American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
November 13, 2024
Earnings Call Speaker Segments
Kirin Smith
executiveThanks, Nick, and I'm glad everyone could join us today. This morning, before trading began, we issued our press release about AMS's results for the third quarter of 2024. If you'd like a copy, it's available on the company's website, www.ashs.com, in the Press Releases section under the Investors tab. Before I turn the call over to management, I'd like to make a few remarks about forward-looking statements. Please note that anything said on this call about the company's future expectations, plans, and prospects constitutes forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. What we actually report could end up looking quite different from what these forward-looking statements suggest, and that's due to a number of significant factors — among them the ones covered in the documents the company has filed with the SEC. Those documents include the quarterly report on Form 10-Q covering the three months that closed on June 30, 2024, the annual report on Form 10-K for the year that ended December 31, 2023, and the definitive proxy statement tied to the shareholders' annual meeting held on June 25, 2024. Nothing in this conference call is something the company promises to come back and revise later. Also, before turning things over to Ray, I'd like to go over how our Q&A works: every participant gets the chance to pose one question, plus one follow-up. We're always available to address further inquiries outside of this session whenever needed. At this point, I'll turn things over to our Executive Chairman and Chief Executive Officer, Ray Stachowiak. Go ahead, Ray.
Ray Stachowiak
executiveThanks, Kirin. Hi everybody, and good afternoon. We're glad you could join us today for this call about our third-quarter 2024 results. I'll begin with a few opening remarks, then I'll turn things over to Bob Hiatt, our Chief Financial Officer, who will take you through a financial review of what we delivered in the third quarter. After those prepared comments, we'll open it up for your questions. Before we dive into the quarter, I'd like to highlight an important addition to our executive management team that we announced in mid-October. Gary Delanois has joined us as Executive Vice President and Chief Operating Officer. Gary's knowledge spans physician and payor connections, billing and collections, plus policies and procedures — a skill set that aligns squarely and seamlessly with the expansion plan we're following as we keep growing and refining the entire operation. A veteran leader, Gary carries extensive, progressively responsible experience in healthcare management, and he has brought creative yet tested answers to physician groups, health systems, ACOs, and health plans. On top of that, he has served considerably on boards of directors for multiple healthcare systems based in California, West Virginia, Rhode Island, and Michigan. Prior to stepping into this position, Mr. Delanois held the title of Senior Vice President, U.S. He oversaw day-to-day operations at 21st Century Oncology, managing a network of over 140 radiation therapy centers, collaborating with more than 160 radiation oncologists, and providing care to thousands of patients each day. Clearly, his qualifications are exceptional, and we are delighted to have him join our team. In addition, we shared news that Ranjit Pradhan has been elevated to Senior Vice President, Sales and Marketing. Ranjit played a vital role in the company's achievements, as he recently renewed and expanded five of the 10 domestic Gamma Knife agreements held by American Shared during the past 18 months. In this new position, he will oversee the company's strategic business development and marketing efforts and propel growth in new business, further enhancing the company's impact and reach in oncology services. Alright, let's walk through what we saw in the quarter. Revenue growth came in strong once again, and our confidence in where things are headed overall continues to build. We've kept making meaningful strides and progress across a number of key areas, and we're really looking forward to the year ahead. That said, we've certainly had our share of obstacles to work through. We're dealing with seasonal patterns and shifts in procedure volume, we're folding in the Rhode Island acquisition, we're putting money into upgraded equipment that was badly needed, and we're putting more operating efficiencies in place. Those things did weigh on our margins and profitability in the near term, but they set us up to win over the longer haul. We kept up the momentum from the first two quarters, delivering yet another strong period of top-line expansion. Revenue came in at $6.99 million, a healthy improvement over the $5.1 million we posted in the same quarter of 2023. That works out to a 36% increase in revenue compared with a year earlier, driven by the early gains we're already seeing from the Rhode Island deal that closed back in May, along with contributions from our new Puebla, Mexico site. On the gross margin side, we saw a $732,000 decrease, which took a hit from softer Gamma Knife treatment volumes and also mirrors the shifting mix brought about by the robust growth in our retail segment. On top of that, for this quarter we ended up with a slight net loss — $207,000, which comes to $0.03 per share — compared with a small profit in the third quarter of 2023 of $118,000, or $0.02 per share. Our balance sheet remains strong; when the third quarter closed, we had over $14.1 million in cash and equivalents, equal to roughly $2.17 per share. As of September 30, 2024, we had also drawn $4.5 million against our $7 million line of credit. We continue to deploy these resources carefully as we pursue additional long-term revenue streams. Having a balance sheet this solid is a genuine plus — it gives us plenty of capital to put toward strategic moves such as the Rhode Island acquisition, plus whatever other business opportunities come our way. Just to refresh everyone: the Rhode Island acquisition is a great illustration of how we deployed $3 million and strategically brought in fair market value and net assets totaling $8 million. Plainly put, that was an outstanding use of capital. On top of that, of the assets we picked up, $3.4 million of it was cash. Cash. We've been installing operating efficiencies to get this business running as well as it can. To give you specifics, we put $1.1 million into CapEx at our Rhode Island centers. We replaced two extremely old CT simulators — those are needed for treatment planning — and we purchased the third CT sim, which until then was being leased. On top of that, we added software packages aimed at improving efficiency and patient care. We've also begun stepping back from the pricier temporary staffing that GenesisCare, the previous owner of the Rhode Island facilities, relied on during its struggles. Getting permanent employees on board was a challenge for us, since they cost less and provide greater stability over the long run. And just recently, we signed service and maintenance agreements for our linear accelerators, which bolsters our reliability and high uptime so we can deliver better-quality service. I want to point out that we picked up three radiation therapy centers, and those centers were profitable. They had positive income and positive EBITDA, but the company running them was in the middle of a bankruptcy proceeding. So let's keep that in mind. Our team also remains focused on making our core business stronger by partnering with clients to increase how much they use our equipment. Thanks to that focused approach, we've signed five lease extensions in the past 18 months with our 10 domestic Gamma Knife clients, and more are in the pipeline. Once again, this hasn't come without difficulty. This quarter, we worked through losing a site we had in third quarter 2023. An equipment upgrade required us to take some planned downtime. Beyond that, treatment volumes came in lower, driven in part by a shortage of physicians along with seasonal staffing issues affecting certain locations. Even with the difficulties our team is working through, we view these longer-term agreements as proof of our partnership-oriented business model, our capacity to remain financially flexible, and a growth driver that matters a great deal. During October, we've already seen Gamma Knife treatment volumes rise. A substantial growth opportunity sits within our international operations. We also anticipate that this momentum will carry forward. First, it's worth noting that we are the only holder of Gamma Knife systems in both Peru and Ecuador. Only a handful of months back, we shared news that our third facility outside the US, located in Puebla, Mexico, had started seeing patients. The recently installed linear accelerator—LINAC for short—comes equipped with VMAT, IGRT, and radiosurgery features, delivering the most sophisticated radiation therapy on offer within the area we serve. During the first part of July, we revealed our fourth overseas site upon signing a joint venture deal for a Gamma Knife operation in Guadalajara, Mexico. That site will house one of just three Gamma Knife systems in a nation of 130 million people. I also want to mention that we've been taking on rising expenses tied to our Rhode Island acquisition, above $300,000 or $400,000 each quarter. We anticipate a reduction greater than $300,000 during our fourth quarter. I'd further like to remind our investors that earlier this year we told you about three distinct business chances. The first involved finalizing our 60% majority stake in the three radiation therapy cancer centers located in Rhode Island; that deal closed in early May; these represent our first direct patient services, or retail centers, within the United States. This fresh business, the first to emerge from our enlarged team and new pipeline, plainly demonstrates the strength of our growth strategy. Now I want to discuss the second one. The second concerns the CON Certificate of Need we received to construct a fourth radiation therapy center in Bristol, Rhode Island. The third opportunity is a particularly strong one. We've filed for a certificate of need to build a proton beam radiation therapy facility in Rhode Island; this center would be the sole system of its kind across New York City and Boston, representing a significant growth prospect. Right now, picture this—we'd own and run this proton beam radiation therapy center entirely, at 100%; we expect to share more news on this matter when the time is right. As we think about what's ahead in the next several months and into next year, we expect to see better growth internationally. That's going to come from additional treatment capabilities we've added in Ecuador, steady volume out of our Peru center, and our two new locations in Guadalajara and Puebla. We just closed the Rhode Island acquisition, and that gives us three more revenue streams, plus there are other exciting new business opportunities that are still moving through a long sales cycle. Our backlog continues to give us a lot of confidence in the overall business for the long term. So with that, I'll turn things over to Bob, who will walk us through the financials.
Bob Hiatt
executiveThanks, Ray, and hello everyone on the line this afternoon. Third-quarter revenue climbed 36.3%, reaching $6.99 million, compared with $5.13 million in the same period a year earlier. A pair of factors contributed to that top-line result: our acquisition in Rhode Island, which closed back in May, and the newly opened site in Puebla, Mexico. Turning to direct patient services — what we call our retail segment — sales came in at $3.7 million for the quarter that concluded on September 30th, 2024, against $988,000 a year ago, which works out to a 273% jump. Most of that retail expansion stemmed from the revenue generated by the Rhode Island businesses we picked up on May 7th, 2024, as well as from getting the Puebla operations up and running during the third quarter. Turning to leasing revenue—that's what we now call our medical equipment leasing segment—it reached $3.31 million in Q3 2024. A year earlier, the figure stood at $3.95 million, so that works out to a 16.1% drop. The decrease stemmed from reduced Gamma Knife volumes. Worth noting: the prior-year comparison leaves out the $200,000 equipment sale that was booked in the third quarter of 2023. As for our Florida proton therapy system, third-quarter revenue was $2.3 million, a 4.4% increase, mainly attributable to ongoing cyclical shifts in volume. In Q3, we delivered 1,252 proton therapy fractions. That compares with 1,188 in the same quarter of 2023, which works out to growth of 5.4%, once again reflecting the usual cyclical swings. Gamma Knife revenue overall dropped 32.9%, landing at $1.82 million. Several factors drove that: a contract that lapsed during the third quarter of 2023, a scheduled equipment upgrade that took one of our sites offline for two months, and staffing gaps at two additional sites. For Q3 2024, gross margin fell to $1.37 million. In Q3 2023, it was $2.10 million. Two factors weighed on the recent figure: reduced Gamma Knife treatment volumes, plus strong expansion in our patient services retail segment, which carries a lower gross margin. Selling and administrative costs climbed to $1.92 million in the third quarter of 2024, up from $1.74 million during the same quarter a year earlier. The increase stemmed from acquisition and development costs tied to Rhode Island, along with legal fees. Interest expense came in at $336,000 for the 2024 period, whereas it was $277,000 in last year's comparable period. Higher interest rates and more borrowing against the company's variable rate debt drove this rise. For the third quarter of 2024, we posted an operating loss of $889,000, versus a modest operating income of $90,000. That year-over-year drop stems from higher operating costs tied to the facilities the company recently acquired in Rhode Island and its new site in Puebla, Mexico, along with reduced Gamma Knife treatment volumes. In Q3, the gain we booked on the market purchase from the Rhode Island deal rose by $263,000 after taxes, mainly driven by adjustments in the valuation report related to certain real estate assets and non-controlling interest, as well as updated assumptions regarding how much of the acquired receivables we will collect. Looking at the third quarter of 2024, our income tax situation was a benefit of $169,000. A year earlier in that same quarter, we recorded income tax expense of $60,000. American Shared Hospital Services reported a net loss attributable to the company of $207,000 for Q3 2024, which works out to $0.03 per diluted share. In Q3 2023, by contrast, we had net income of $118,000, or $0.02 per diluted share. The year-over-year drop was primarily due to losses in the leasing segment, which came from lower Gamma Knife volume as well as increased depreciation related to planned equipment upgrades. Our fully diluted weighted average common shares outstanding were essentially unchanged, at $6,482,000 for Q3 2024 and $6,432,000 for Q3 2023. On a non-GAAP basis, adjusted EBITDA landed at $1.37 million for Q3 2024, compared with $1.67 million for Q3 2023. Moving on to the results covering nine months: for the period ending September 30, 2024, revenue climbed 23.3%, reaching $19.27 million, whereas the same stretch of 2023 generated $15.63 million. The retail side — what we call direct patient services — accounted for $7.81 million across the nine months that closed September 30th, 2024, compared with $2.44 million the prior year, which works out to a 220% jump. Driving the total top-line improvement were mostly the Rhode Island companies acquired on May 7th, 2024, a 25.1% rise in revenue from Peru and Ecuador, plus Puebla beginning operations in Q3. In the first nine months of 2024, Gamma Knife revenue dropped 14.6%, coming in at $7.13 million, versus $8.35 million during the same stretch of 2023. Procedures using Gamma Knife reached 831 in that January-to-September window of 2024, a 9.5% decline from 918 a year earlier. The decrease stemmed from the Q3 procedure shortfalls we went over previously. Proton therapy revenue climbed 4.4%, hitting $7.39 million across the first nine months of 2024, up from $7.08 million in the corresponding period of 2023. Proton therapy fractions came to 3,764 in the initial nine months of 2024, which represents an 8.1% drop compared with 4,094 in the same period of 2023. For American Shared Hospital Services, net income attributable to the company during the first nine months of 2024 reached $3.51 million, equal to $0.54 per diluted share. In the first nine months of 2023, that figure stood at $195,000, or $0.03 per diluted share. The Rhode Island acquisition generated a market purchase gain, and the Rhode Island facilities that were acquired contributed net income — together these drove the considerable increase. Adjusted EBITDA, on a non-GAAP basis, was $5.12 million for the first nine months of 2024, compared with $5.51 million in the same period of 2023. Cash and cash equivalents plus restricted cash came to $14.1 million as of September 30, 2024, an increase from $13.8 million as of December 31, 2023. Shareholders' equity, leaving out non-controlling interest and subsidiaries, stood at $26.42 million, or $4.14 for each outstanding share, as of September 30th, 2024, compared with $22.62 million, or $3.59 for each outstanding share, on December 31st, 2023. That brings the formal portion of our presentation to a close. Thanks once more for being with us today. We're eager to share updates on our progress over the coming quarters. Nick, at this point we'd like to hand the call back to you and open things up for questions.
Marla Marin
analystThanks. I'd like to build on a point you made during the prepared remarks, Ray, regarding some startup expenses. My guess is those relate to launching new business operations in Rhode Island and Puebla. But I also want to ask whether, when a new business comes aboard, there tends to be a ramp-up window in which that new facility, or those new facilities, gradually climb toward peak operating efficiency. Puebla, as I recall, went live during the quarter. So would you agree that's part of what we're observing at present in Q3?
Ray Stachowiak
executiveYou've identified, I'd say, two buckets of expenses that weighed on our third-quarter results. The first bucket is what we internally call Rhode Island acquisition costs; it seems we've been absorbing $300,000 or $400,000 each quarter. Legal fees make up a large portion. Accounting fees make up another large portion; valuations have been necessary since we're a public company. We must value the assets and engage outside consultants for that purpose, helping us not only value the assets but also put together our opening balance sheet so it satisfies the audit requirements, the review requirements that come with being a public company. The second bucket involves expenses tied to integrating our Rhode Island radiation therapy centers. The costs we've been absorbing stem from the fact that a company undergoing bankruptcy proceedings had been managing these three centers, so its equipment was outdated, as I've discussed, as described regarding the CT simulators. Two of them required replacement. We placed our equipment under service and maintenance agreements. As for the employees we brought on, we hired nearly every single person who had worked for GenesisCare, though many personnel there weren't actually employees. These centers had contracts with outside third-party staffing firms and locum tenens at exorbitant costs to the center, since they kept losing radiation therapists. They kept losing physicists, and we brought on board the radiation therapists and physicists already there, yet we needed to shift away from those third-party staffing expenses toward employees. As one more illustration, we acquired, I believe there are 4 temporary or outside third-party, 4 radiation therapists provided by outside third parties. Out of those 4, we've now hired 2, I'll say, headcount as employees, and we're near bringing on a third. But that extra expense is one we inherited; we understand how to resolve it, yet getting it under proper management will require some time. Does that address your question?
Marla Marin
analystYes, thank you. That's quite useful, thanks. Then I have just one more question about the Puebla facility. At this point, you've been running that site, I believe, since August. Do you have any sort of insight into how it's going relative to what you anticipated — anything you feel good about?
Ray Stachowiak
executiveWhat I'd say is that the launch ran behind schedule. Revenue generation didn't begin for us until the beginning of July, but honestly, the outcome has made us quite happy. Since we opened, the money coming in from that location has climbed month after month; its performance has us very satisfied.
Tony Kamin
analystHello, Ray. I'd like to ask about the Rhode Island situation from a somewhat different perspective. During your prepared remarks, I believe you brought this up on a few occasions, saying something like, "Keep in mind, this thing was running while in bankruptcy, or something along those lines." So here's what I want to know: a moment ago, when you brought up the equipment being somewhat dated or whatever the case may be, how was that affecting the opposite side of the operation? I don't mean expenses — I mean utilization, from the standpoint of patients and physicians sending patients your way, plus the ambiguity surrounding bankruptcy. Do you believe you're able to attract additional business, meaning more referrals and everything else, when it comes to the customer side and the physicians doing the referring?
Ray Stachowiak
executiveThanks, Tony. I believe there's a clear opportunity for us to grow our volumes. Here's an illustration. A CT simulator we swapped out had been unusable for multiple months. Basically, it was out of service. Before we bought the place, it wasn't functional at all, so it became the initial unit we replaced. There was also a doctor sending referrals who refused to use that location due to the broken CT simulator. Once we put in a new CT simulator, that same doctor began sending his patients to our center again. So honestly, that's a perfect example of what we're doing to drive up our volumes.
Tony Kamin
analystAlso, are there any additional promotional efforts underway? In other words, are you currently making physicians aware that, "Hey, this facility has been improved and everything"? Then, as a separate matter that isn't truly connected, could you say something regarding the Gamma Knife area and whether that quarter proved difficult for certain reasons? Do you folks possess some kind of strategy concerning Gamma Knife that you believe could assist in reversing the situation somewhat?
Ray Stachowiak
executiveAlright, regarding the two questions about raising awareness for our radiation therapy centers in Rhode Island — that is definitely something we're actively doing. It's important to remember that our joint venture partners, who hold the other 20% ownership stake, represent the state's second largest healthcare system. They know all about this acquisition and keep sending patients our way. Our other 20% partner occupies the same position as the third largest healthcare system in Rhode Island, and the situation is identical there. As for the biggest healthcare system in the state, they're fully informed about what we're doing, and they're just as open as we are to discussing the relationship and ways to expand it. So awareness of our presence is spreading widely across Rhode Island, particularly among the Health Services Council, which reviews our CON filings. They are extremely informed. Leaders throughout the state are also aware of what we're doing in Rhode Island. Turning to your question about Gamma Knife, Tony, the third quarter was almost what I would call an anomaly when it came to treatment volumes from physicians, radiation oncologists, and neurosurgeons — some took vacations during July and August, one physician was out on maternity leave, and one of our sites experienced downtime while we upgraded its system. So it was a mix of different factors, all of which are, I'd say, surmountable. Not sure that's an actual word, but I believe we can get past those circumstances. I'm not pleased with the results there, but we looked into it thoroughly. We have a very clear understanding, and I believe a plan is now in place. We're more involved than we've ever been in building awareness of our Gamma Knife within these communities.
Ray Stachowiak
executiveAnthony, I appreciate the question and the point you've raised. Our approach as a company requires those who invest with us to have patience and to think in truly long time frames. I can detect the frustration in your voice. Stay with us over the long haul. I realize a lot of you already have, but consider the shift we are undertaking in how our business operates. When you examine that shift, you'll see we are growing our geographic footprint. We're also broadening what we offer product-wise. Four years back, our portfolio consisted of Gamma Knife and a proton beam. As of today, we've brought in four linear accelerators: three located in Rhode Island, plus one more in Puebla, Mexico. Beyond that, we intend to bring in a fifth linear accelerator at our fourth radiation therapy center, which is in Bristol, Rhode Island. We're also moving forward with our second proton beam system. Another diversification move we're making involves shifting away from a leasing segment company that was dominated by a leasing segment toward becoming more dominant and prevalent in the retail segment. Our proton beam center in Rhode Island, assuming the CON comes through, is precisely another proton. Those who invest with us keep asking, "At what point will our second proton beam arrive?" We're getting one right here in Rhode Island. And incidentally, it won't be leased in a way where we receive a percentage of the revenue that the hospital care system collects. No — we will be 100% owner and operator, provided that CON gets approved. Just keep watching for news on that front. What about a modest buyback? I mean, apologies, I didn't intend to interrupt you. What about a modest buyback, which, once more, considering the cash you have available and your capacity to borrow, strikes me as an investor, and for you folks too, if you're purchasing the stock at cash, assuming the business has a future, it would be an incredible use of your — and you're acquiring it far below tangible books. So to me it looks like a very good use of your funds. I'm not suggesting you wager everything. I'm just suggesting a modest buyback. Yeah. Anthony, point taken. Okay. Thank you.
Ray Stachowiak
executiveThanks, Nick. And thank you all for being with us on this call; our outlook genuinely has us thrilled. American Shared is sitting at a pivotal turning point, particularly after the Rhode Island deal and the additional expansion chances we are actively chasing. We recognize completely that the path won't simply rise steadily. Obstacles are going to come up along the way. Our confidence is high that the correct approach is now in place. We now have a solid team able to carry out our growth plans; we're eager to share updates as progress continues. Should any questions arise, please reach out without hesitation. We will make time for more discussion. We appreciate your ongoing interest in American Shared Hospital Services. Enjoy the rest of your day and your week. Goodbye.
Operator
operatorThat brings this call to an end. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.